Key result
Pretreatment with aliskiren ameliorated ischemia/reperfusion-induced renal injury in rats by decreasing nitric oxide and angiotensin II levels and down-regulating IL-1β, iNOS, and NFkB expression.
Why the study?
Does aliskiren pretreatment ameliorate renal ischemia/reperfusion injury in a rat model?
RCT
randomly divided
Does aliskiren pretreatment ameliorate renal ischemia/reperfusion injury in a rat model?
In a rat model, aliskiren pretreatment protected against renal ischemia/reperfusion injury by modulating inflammatory and oxidative stress pathways.
Answers are grounded in this paper and cite their sources.
Caution against clinical use in renal I/R; leaves open translation from this rat model to human trials.
PURPOSE: To determine the protective effect of aliskiren on ischemia-reperfusion (I/R) injury in a rat renal (I/R) model. METHODS: Rats were randomly divided into five groups: sham control group; sham control with aliskiren pretreatment; I/R group and I/R with two doses of aliskiren pretreatment. Rats were unilaterally nephrectomized and subjected to 45 min of renal pedicle occlusion followed by 24 h reperfusion. Aliskiren (50 and 100 mg/kg) was administered orally by gavage 24 and 1 h prior to ischemia. After 24 h reperfusion, kidney samples were taken for the determination of malondialdehyde (MDA) level, superoxide dismutase (SOD), glutathione (GSH) activity and histological evaluation. The level of serum creatinine (SCR) and blood urea nitrogen (BUN), renin and angiotensin II (AT-2) was measured in serum samples. RESULTS: Kidneys from I/R groups showed significant increase in MDA level and significant decrease in GSH, and SOD activity. IL-1β, iNOS and NFkB gene expression significantly increased in the I/R groups in the rat kidney tissue. Aliskiren treatment showed a significant down-regulatory effect on IL-1β, iNOS and NFkB mRNA expression. Compared with the sham group, SCR and BUN, renin and AT-2 were significantly increased in the I/R rats, accompanied by histopathological damage to the kidney. CONCLUSION: Pretreatment with aliskiren ameliorated I/R-induced renal injury through decreasing nitric oxide and AT-2 levels and by the reduction of injury induced by I/R injury and ameliorated renal histopathological molecular and biochemical changes.
No takes yet. Share an insight, caveat, or question.
Ziypak et al. (2014) conducted an RCT in renal ischemia/reperfusion injury. Aliskiren vs. sham control and ischemia/reperfusion without pretreatment was evaluated on malondialdehyde (MDA) level, superoxide dismutase (SOD), glutathione (GSH) activity, histological evaluation, serum creatinine, blood urea nitrogen, renin, and angiotensin II. Pretreatment with aliskiren ameliorated ischemia/reperfusion-induced renal injury in rats by decreasing nitric oxide and angiotensin II levels and down-regulating IL-1β, iNOS, and NFkB expression.
Synapse has enriched 10 related papers. Consider them for comparative context: